Molecular and pathologic insights from latent HIV-1 infection in the human brain

Neurology

Volumn 80, Issue 15, 2013, Pages 1415-1423

  Desplats, Paula ^a   Dumaop, Wilmar ^b   Smith, David ^c   Adame, Anthony ^a   Everall, Ian ^b,d   Letendre, Scott ^c   Ellis, Ronald ^a   Cherner, Mariana ^b   Grant, Igor ^b   Masliah, Eliezer ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD74 ANTIGEN; GAG PROTEIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; VIRUS DNA; VIRUS RNA;

ADULT; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; COGNITIVE DEFECT; CONFOCAL MICROSCOPY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOBLOTTING; IMMUNOCHEMISTRY; MALE; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VIRUS ENCEPHALITIS; VIRUS LATENCY;

ADULT; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; BRAIN; CASE-CONTROL STUDIES; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; INTERLEUKIN-6; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; RECEPTORS, CXCR4; REPRESSOR PROTEINS; RNA, MESSENGER; SYNAPTOPHYSIN; TUMOR SUPPRESSOR PROTEINS;

EID: 84876263917     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31828c2e9e     Document Type: Article

References (33)

1. Fauci AS. The human immunodeficiency virus: infectivity and mechanisms of pathogenesis. Science 1988; 239: 617-622.
2. Ellis R, Langford D, Masliah E. HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat Rev Neurosci 2007; 8: 33-44.
3. Price RW, Spudich S. Antiretroviral therapy and central nervous system HIV type 1 infection. J Infect Dis 2008; 197(suppl 3):S294-S306.
4. Everall I, Vaida F, Khanlou N, et al. Cliniconeuropathologic correlates of human immunodeficiency virus in the era of antiretroviral therapy. J Neurovirol 2009; 15: 360-370.
5. Langford TD, Letendre SL, Larrea GJ, Masliah E. Changing patterns in the neuropathogenesis of HIV during the HAART era. Brain Pathol 2003; 13: 195-210.
6. Masliah E, DeTeresa RM, Mallory ME, Hansen LA. Changes in pathological findings at autopsy in AIDS cases for the last 15 years. AIDS 2000; 14: 69-74.
7. Jordan A, Bisgrove D, Verdin E. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J 2003; 22: 1868-1877.
8. Alexaki A, Liu Y, Wigdahl B. Cellular reservoirs of HIV-1 and their role in viral persistence. Curr HIV Res 2008; 6: 388-400.
9. Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008; 65: 65-70.
10. Redel L, Le Douce V, Cherrier T, et al. HIV-1 regulation of latency in the monocyte-macrophage lineage and in CD41 T lymphocytes. J Leukoc Biol 2010; 87: 575-588.
11. Marban C, Suzanne S, Dequiedt F, et al. Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing. EMBO J 2007; 26: 412-423.
12. Moore DJ, Masliah E, Rippeth JD, et al. Cortical and subcortical neurodegeneration is associated with HIV neu-rocognitive impairment. AIDS 2006; 20: 879-887.
13. Patrick C, Crews L, Desplats P, et al. Increased CDK5 expression in HIV encephalitis contributes to neurodegen-eration via tau phosphorylation and is reversed with Roscovitine. Am J Pathol 2011; 178: 1646-1661.
14. Desplats PA, Lambert JR, Thomas EA. Functional roles for the striatal-enriched transcription factor, Bcl11b, in the control of striatal gene expression and transcriptional dysregulation in Huntington's disease. Neurobiol Dis 2008; 31: 298-308.
15. Masliah E, Ge N, Morey M, DeTeresa R, Terry RD, Wiley CA. Cortical dendritic pathology in human immunodeficiency virus encephalitis. Lab Invest 1992; 66: 285-291.
16. Achim CL, Heyes MP, Wiley CA. Quantitation of human immunodeficiency virus, immune activation factors, and qui-nolinic acid in AIDS brains. J Clin Invest 1993; 91: 2769-2775.
17. Mucke L, Abraham CR, Ruppe MD, et al. Protection against HIV-1 gp120-induced brain damage by neuronal expression of human amyloid precursor protein. J Exp Med 1995; 181: 1551-1556.
18. Tang B, Di Lena P, Schaffer L, Head SR, Baldi P, Thomas EA. Genome-wide identification of bcl11b gene targets reveals role in brain-derived neurotrophic factor signaling. PLoS One 2011; 6:e23691.
19. Everall I, Salaria S, Roberts E, et al. Methamphetamine stimulates interferon inducible genes in HIV infected brain. J Neuroimmunol 2005; 170: 158-171.
20. Avram D, Fields A, Senawong T, Topark-Ngarm A, Leid M. COUP-TF (chicken ovalbumin upstream promoter transcription factor)-interacting protein 1 (CTIP1) is a sequence-specific DNA binding protein. Biochem J 2002; 368: 555-563.
21. Wiley CA, Achim CL, Christopherson C, et al. HIV mediates a productive infection of the brain. AIDS 1999; 13: 2055-2059.
22. Banerjee A, Nonnemacher MR, Wigdahl B. HIV latency and reactivation: role in neuropathogenesis. In: Meucci O, ed. Chemokine Receptors and NeuroAIDS: Beyond Co-Receptor Function and Links to Other Neuropathologies. New York: Springer; 2010: 87-118.
23. McPhail ME, Robertson KR. Neurocognitive impact of antiretroviral treatment: thinking long-term. Curr HIV/AIDS Rep 2011; 8: 249-256.
24. Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 2010; 24: 1243-1250.
25. Irish BP, Khan ZK, Jain P, et al. Molecular mechanisms of neurodegenerative diseases induced by human retroviruses: a review. Am J Infect Dis 2009; 5: 231-258.
26. Koenig S, Gendelman HE, Orenstein JM, et al. Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science 1986; 233: 1089-1093.
27. Roulston A, Lin R, Beauparlant P, Wainberg MA, Hiscott J. Regulation of human immunodeficiency virus type 1 and cytokine gene expression in myeloid cells by NF-kappa B/Rel transcription factors. Microbiol Rev 1995; 59: 481-505.
28. Kasyanov A, Tamamura H, Fujii N, Xiong H. HIV-1 gp120 enhances giant depolarizing potentials via chemokine receptor CXCR4 in neonatal rat hippocampus. Eur J Neurosci 2006; 23: 1120-1128.
29. Lu SM, Tremblay ME, King IL, et al. HIV-1 Tat-induced microgliosis and synaptic damage via interactions between peripheral and central myeloid cells. PLoS One 2011; 6:e23915.
30. Power C, Hui E, Vivithanaporn P, Acharjee S, Polyak M. Delineating HIV-associated neurocognitive disorders using transgenic models: the neuropathogenic actions of Vpr. J Neuroimmune Pharmacol 2012; 7: 319-331.
31. Yang B, Akhter S, Chaudhuri A, Kanmogne GD. HIV-1 gp 120 induces cytokine expression, leukocyte adhesion, and transmigration across the blood-brain barrier: modulatory effects of STAT1 signaling. Microvasc Res 2009; 77: 212-219.
32. Morrison BE, Majdzadeh N, D'Mello SR. Histone deacetylases: focus on the nervous system. Cell Mol Life Sci 2007; 64: 2258-2269.
33. Sahu GK, Cloyd MW. Latent HIV in primary T lymphocytes is unresponsive to histone deacetylase inhibitors. Virol J 2011; 8: 400.